Fifteen years after it rose and went limp, the biotech sector, globally, as well as in India has seen a bull run of sorts. In January this year, some 10 healthcare companies went public on the NASDAQ. Meanwhile, India has become the world's 12th biggest biotechnology economy having the second highest number of USFDA-approved plants. But will this boom continue? Or will it prove to be just a bubble like it was in 2000, impacting drug manufacturing companies badly. Richard Mahapatra and Kundan Pandey take stock